FOLH1 and prostate carcinoma: The discovery of PSMA as molecular target in the diagnosis and therapy of prostate cancer, as well as the application of radiolabeled PSMA inhibitors, have revolutionized the management of this disease resulting in a significant improvement especially in staging and assessment of prostate cancer [38].